57 results on '"Selleng, K."'
Search Results
2. Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study.
- Author
-
Giles JB, Rollin J, Martinez KL, Selleng K, Thiele T, Pouplard C, Sheppard JI, Heddle NM, Phillips EJ, Roden DM, Gruel Y, Warkentin TE, Greinacher A, and Karnes JH
- Subjects
- Humans, Female, Retrospective Studies, Heparin adverse effects, Anticoagulants adverse effects, Immunoglobulin A, Platelet Factor 4, Immunoglobulin G, Demography, Thrombocytopenia chemically induced, Thrombocytopenia diagnosis
- Abstract
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated immune response against platelet factor 4 (PF4) bound to heparin anticoagulants. A priori identification of patients at-risk for HIT remains elusive and a number of risk factors have been identified, but these associations and their effect sizes have limited validation in large cohorts of suspected HIT patients. The aim of this study was to investigate existing anti-PF4/heparin antibody thresholds and model the relationship of demographic variables and anti-PF4/heparin antibody levels with functional assay positivity across multiple institutions in the absence of detailed clinical data. In a large collection of suspected HIT patients (n = 8904), we tested for associations between laboratory and demographic variables and functional assay positive status as well as anti-PF4/heparin antibody levels. We also tested for correlation between IgG-specific and polyspecific (IgG/IgA/IgM) anti-PF4/heparin antibody values and their ability to predict functional assay positive status using area under the receiver operating characteristic (AUROC). Logistic regression identified increasing anti-PF4/heparin antibody OD levels (OR = 51.84 [37.27-74.34], p < 2.0 × 10
-16 ) and female sex (OR = 1.47 [1.19-1.82], p = 3.5 × 10-4 ) as risk factors for positive functional assay in the largest cohort with consistent effect sizes in two other cohorts. In a subset of 1175 patients, polyspecific and IgG-specific anti-PF4/heparin antibody values were heterogeneous (mean coefficient of variation = 31.9 %), but strongly correlated (rho = 0.878; p < 2 × 10-16 ) with similar prediction of functional assay positivity (polyspecific AUROC = 0.976 and IgG-specific AUROC = 0.980). Thus, we recapitulate previously identified risk factors of functional assay positivity, providing precise effect sizes in a large observational population of suspected HIT patients. Our data reinforce the necessity of functional assay confirmation and suggest that, despite heterogeneity, polyspecific and IgG-specific anti-PF4/heparin antibody assays predict functional assay positive status similarly, even in the absence of 4Ts scores and detailed clinical data., Competing Interests: Declaration of competing interest Theodore (Ted) E. Warkentin, MD, has received lecture honoraria from Instrumentation Laboratory, and royalties from Informa (Taylor & Francis) and UptoDate (Wolters Kluwer); has provided consulting services to Aspen Canada, Aspen Global, CSL Behring, Ergomed, Paradigm Pharmaceuticals, Octapharma, and Veralox Therapeutics; has received research funding from Instrumentation Laboratory; and has provided expert witness testimony relating to heparin-induced thrombocytopenia (HIT) and non-HIT thrombocytopenic and coagulopathic disorders. Andreas Greinacher reports grants and non-financial support from Aspen, Boehringer Ingelheim, MSD, Bristol Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc., Rovi, Sagent, Biomarin/Prosensa, personal fees from Aspen, Boehringer Ingelheim, MSD, Macopharma, BMS, Chromatec, Instrumentation Laboratory, non-financial support from Boehringer Ingelheim, Portola, Ergomed, GTH e.V. outside the submitted work. Kathleen Selleng reports a research funding from Immucor, personal fees from Aspen and Viatris and non-financial support from SOBI outside the submitted work. There are no other conflicts., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
3. Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis.
- Author
-
Schönborn L, Seck SE, Thiele T, Kaderali L, Hoffmann T, Hlinka A, Lindhoff-Last E, Völker U, Selleng K, Buoninfante A, Cavaleri M, and Greinacher A
- Subjects
- Humans, COVID-19 Vaccines adverse effects, Longitudinal Studies, Prospective Studies, SARS-CoV-2, Purpura, Thrombocytopenic, Idiopathic chemically induced, Purpura, Thrombocytopenic, Idiopathic diagnosis, COVID-19, Thrombocytopenia chemically induced, Thrombosis etiology, Influenza Vaccines
- Abstract
Background: Rapid diagnosis and treatment has improved outcome of patients with vaccine-induced immune thrombocytopenia and thrombosis (VITT). However, after the acute episode, many questions on long-term management of VITT remained unanswered., Objectives: To analyze, in patients with VITT, the long-term course of anti-platelet factor 4 (PF4) antibodies; clinical outcomes, including risk of recurrent thrombosis and/or thrombocytopenia; and the effects of new vaccinations., Methods: 71 patients with serologically confirmed VITT in Germany were enrolled into a prospective longitudinal study and followed for a mean of 79 weeks from March 2021 to January 2023. The course of anti-PF4 antibodies was analyzed by consecutive anti-PF4/heparin immunoglobulin G enzyme-linked immunosorbent assay and PF4-enhanced platelet activation assay., Results: Platelet-activating anti-PF4 antibodies became undetectable in 62 of 71 patients (87.3%; 95% CI, 77.6%-93.2%). In 6 patients (8.5%), platelet-activating anti-PF4 antibodies persisted for >18 months. Five of 71 patients (7.0%) showed recurrent episodes of thrombocytopenia and/or thrombosis; in 4 of them (80.0%), alternative explanations beside VITT were present. After further COVID-19 vaccination with a messenger RNA vaccine, no reactivation of platelet-activating anti-PF4 antibodies or new thrombosis was observed. No adverse events occurred in our patients subsequently vaccinated against influenza, tick-borne encephalitis, varicella, tetanus, diphtheria, pertussis, and polio. No new thrombosis occurred in the 24 patients (33.8%) who developed symptomatic SARS-CoV-2 infection following recovery from acute VITT., Conclusion: Once the acute episode of VITT has passed, patients appear to be at low risk for recurrent thrombosis and/or thrombocytopenia., Competing Interests: Declaration Of Competing Interests A.G. reports grants and nonfinancial support from Aspen, Boehringer Ingelheim, Merck-Sharp and Dome, Bristol-Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc, Rovi, Sagent, and Biomarin/Prosensa; personal fees from Aspen, Boehringer Ingelheim, Merck-Sharp and Dome, Macopharma, BMS, Chromatec, and Instrumentation Laboratory; and nonfinancial support from Boehringer Ingelheim, Portola, Ergomed, and GTH e.V., outside the submitted work. T.T. reports personal fees and other from BMS, personal fees and other from Pfizer, personal fees from Bayer, personal fees and other from Chugai Pharma, other from Novo Nordisk, personal fees from Novartis, other from Daichii Sankyo, and other from Laboratoire français du Fractionnement et des Biotechnologies, outside the submitted work. E.L.-L. has received lecture honoraria and advisory fees from Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Portola, CSL Behring, Viatris, Werfen, Norgine, and Aspen and institutional research support from Bayer AG, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, and CSL Behring for a different research project. L.S. receives a young investigator grant of the medical faculty of the Universitätsmedizin Greifswald. There are no other competing interests to disclose., (Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.
- Author
-
Giles JB, Steiner HE, Rollin J, Shaffer CM, Momozawa Y, Mushiroda T, Inai C, Selleng K, Thiele T, Pouplard C, Heddle NM, Kubo M, Miller EC, Martinez KL, Phillips EJ, Warkentin TE, Gruel Y, Greinacher A, Roden DM, and Karnes JH
- Subjects
- Antibodies, Genome-Wide Association Study, Heparin adverse effects, Humans, Immunologic Factors adverse effects, Platelet Factor 4 genetics, Thrombocytopenia chemically induced, Thrombocytopenia genetics
- Abstract
Heparin, a widely used anticoagulant, carries the risk of an antibody-mediated adverse drug reaction, heparin-induced thrombocytopenia (HIT). A subset of heparin-treated patients produces detectable levels of antibodies against complexes of heparin bound to circulating platelet factor 4 (PF4). Using a genome-wide association study (GWAS) approach, we aimed to identify genetic variants associated with anti-PF4/heparin antibodies that account for the variable antibody response seen in HIT. We performed a GWAS on anti-PF4/heparin antibody levels determined via polyclonal enzyme-linked immunosorbent assays. Our discovery cohort (n = 4237) and replication cohort (n = 807) constituted patients with European ancestry and clinical suspicion of HIT, with cases confirmed via functional assay. Genome-wide significance was considered at α = 5 × 10-8. No variants were significantly associated with anti-PF4/heparin antibody levels in the discovery cohort at a genome-wide significant level. Secondary GWAS analyses included the identification of variants with suggestive associations in the discovery cohort (α = 1 × 10-4). The top variant in both cohorts was rs1555175145 (discovery β = -0.112 [0.018], P = 2.50 × 10-5; replication β = -0.104 [0.051], P = .041). In gene set enrichment analysis, 3 gene sets reached false discovery rate-adjusted significance (q < 0.05) in both discovery and replication cohorts: "Leukocyte Transendothelial Migration," "Innate Immune Response," and "Lyase Activity." Our results indicate that genomic variation is not significantly associated with anti-PF4/heparin antibody levels. Given our power to identify variants with moderate frequencies and effect sizes, this evidence suggests genetic variation is not a primary driver of variable antibody response in heparin-treated patients with European ancestry., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
5. ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia.
- Author
-
Karnes JH, Rollin J, Giles JB, Martinez KL, Steiner HE, Shaffer CM, Momozawa Y, Inai C, Bombin A, Shi M, Mosley JD, Stanaway I, Selleng K, Thiele T, Mushiroda T, Pouplard C, Heddle NM, Kubo M, Phillips EJ, Warkentin TE, Gruel Y, Greinacher A, and Roden DM
- Subjects
- ABO Blood-Group System genetics, Anticoagulants adverse effects, Female, Heparin adverse effects, Humans, Immunoglobulin G, Male, Platelet Factor 4 genetics, Risk Factors, Genome-Wide Association Study, Thrombocytopenia chemically induced, Thrombocytopenia genetics
- Abstract
Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10-8) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10-209) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10-9) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10-8). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
6. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.
- Author
-
Schönborn L, Thiele T, Kaderali L, Günther A, Hoffmann T, Seck SE, Selleng K, and Greinacher A
- Subjects
- COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, Female, Heparin adverse effects, Humans, Immunoglobulin G, Platelet Factor 4, COVID-19 prevention & control, Thrombocytopenia chemically induced, Thrombosis, Vaccines adverse effects
- Abstract
Vaccine-induced thrombotic thrombocytopenia (VITT) is triggered by vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2-S). In this observational study, we followed VITT patients for changes in their reactivity of platelet-activating antiplatelet factor 4 (PF4) immunoglobulin G (IgG) antibodies by an anti-PF4/heparin IgG enzyme immunoassay (EIA) and a functional test for PF4-dependent, platelet-activating antibodies, and new thrombotic complications. Sixty-five VITT patients (41 females; median, 51 years; range, 18-80 years) were followed for a median of 25 weeks (range, 3-36 weeks). In 48/65 patients (73.8%; CI, 62.0% to 83.0%) the functional assay became negative. The median time to negative functional test result was 15.5 weeks (range, 5-28 weeks). In parallel, EIA optical density (OD) values decreased from median 3.12 to 1.52 (P < .0001), but seroreversion to a negative result was seen in only 14 (21.5%) patients. Five (7.5%) patients showed persistent platelet-activating antibodies and high EIA ODs for >11 weeks. None of the 29 VITT patients who received a second vaccination dose with an mRNA COVID-19 vaccine developed new thromboses or relevant increase in anti-PF4/heparin IgG EIA OD, regardless of whether PF4-dependent platelet-activating antibodies were still present. PF4-dependent platelet-activating antibodies are transient in most patients with VITT. VITT patients can safely receive a second COVID-19 mRNA-vaccine shot., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
7. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
- Author
-
Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Völker U, Hentschker C, Michalik S, Steil L, Reder A, Schönborn L, Beer M, Franzke K, Büttner A, Fehse B, Stavrou EX, Rangaswamy C, Mailer RK, Englert H, Frye M, Thiele T, Kochanek S, Krutzke L, Siegerist F, Endlich N, Warkentin TE, and Renné T
- Subjects
- Adenoviridae immunology, Animals, Antigen-Antibody Complex ultrastructure, Autoantibodies biosynthesis, Capillary Leak Syndrome etiology, Capsid Proteins immunology, Cell Line, Transformed, ChAdOx1 nCoV-19 chemistry, ChAdOx1 nCoV-19 immunology, ChAdOx1 nCoV-19 toxicity, Dynamic Light Scattering, Epitopes chemistry, Epitopes immunology, Extracellular Traps immunology, Extravasation of Diagnostic and Therapeutic Materials etiology, Genetic Vectors immunology, HEK293 Cells chemistry, Humans, Imaging, Three-Dimensional, Immunoglobulin G biosynthesis, Inflammation, Mice, Microscopy methods, Platelet Activation, Proteomics, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic immunology, Sinus Thrombosis, Intracranial diagnostic imaging, Sinus Thrombosis, Intracranial immunology, Spike Glycoprotein, Coronavirus immunology, Virus Cultivation, Antigen-Antibody Complex immunology, Autoantibodies immunology, COVID-19 prevention & control, Capsid Proteins adverse effects, ChAdOx1 nCoV-19 adverse effects, Drug Contamination, Genetic Vectors adverse effects, HEK293 Cells immunology, Immunoglobulin G immunology, Platelet Factor 4 immunology, Purpura, Thrombocytopenic, Idiopathic etiology, SARS-CoV-2, Spike Glycoprotein, Coronavirus adverse effects
- Abstract
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using biophysical techniques, mouse models, and analysis of VITT patient samples, we identified determinants of this vaccine-induced adverse reaction. Super-resolution microscopy visualized vaccine components forming antigenic complexes with platelet factor 4 (PF4) on platelet surfaces to which anti-PF4 antibodies obtained from VITT patients bound. PF4/vaccine complex formation was charge-driven and increased by addition of DNA. Proteomics identified substantial amounts of virus production-derived T-REx HEK293 proteins in the ethylenediaminetetraacetic acid (EDTA)-containing vaccine. Injected vaccine increased vascular leakage in mice, leading to systemic dissemination of vaccine components known to stimulate immune responses. Together, PF4/vaccine complex formation and the vaccine-stimulated proinflammatory milieu trigger a pronounced B-cell response that results in the formation of high-avidity anti-PF4 antibodies in VITT patients. The resulting high-titer anti-PF4 antibodies potently activated platelets in the presence of PF4 or DNA and polyphosphate polyanions. Anti-PF4 VITT patient antibodies also stimulated neutrophils to release neutrophil extracellular traps (NETs) in a platelet PF4-dependent manner. Biomarkers of procoagulant NETs were elevated in VITT patient serum, and NETs were visualized in abundance by immunohistochemistry in cerebral vein thrombi obtained from VITT patients. Together, vaccine-induced PF4/adenovirus aggregates and proinflammatory reactions stimulate pathologic anti-PF4 antibody production that drives thrombosis in VITT. The data support a 2-step mechanism underlying VITT that resembles the pathogenesis of (autoimmune) heparin-induced thrombocytopenia., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
8. Blood Product Supply for a Helicopter Emergency Medical Service.
- Author
-
Selleng K, Baschin M, Henkel B, Jenichen G, Thies KC, Rudolph M, Reifferscheid F, Braun J, Hannich M, Winter T, Hahnenkamp K, and Greinacher A
- Abstract
Background: Long patient transport times to trauma centers are a well-known problem in sparsely populated regions with a low hospital density. Transfusion of red blood cell concentrates (RBC) and plasma improves outcome of trauma patients with severe bleeding. Helicopter emergency services (HEMS) are frequently employed to provide early advanced medical care and to reduce time to hospital admission. Supplying HEMS with blood products allows prehospital transfusion and may help to prevent exsanguination or prolonged hemorrhagic shock. We have investigated the maintenance of blood product quality under air transport conditions and the logistical steps to introduce a HEMS blood depot into routine practice., Methods: A risk analysis was performed and a validation plan developed. A special, commercially available transport container for blood products was identified. Maintenance of temperature conditions between 2 and 6°C in the box were monitored at ambient temperatures up to 35°C over 48 h. Quality of blood products before and after helicopter air transport were evaluated including (1) for RBCs: hemoglobin, hematocrit, hemolysis rate; (2) for thawed plasma: aPTT, INR, single clotting factor activities. The logistics for blood supply of the regional HEMS were developed by the transfusion service of the Greifswald University Hospital in collaboration with the in-hospital transport team, the HEMS team, and the HEMS operator., Results: The transport container maintained a temperature below 6°C up to 36 h at 35°C ambient temperature. Vibration during helicopter operation did not impair quality of RBC and thawed plasma. To provide blood products for HEMS at least two transport containers and an additional set of cooling tiles is needed as the cooling tiles need a special temperature priming over 20 h. The two boxes were used at alternate days. To reduce wastage, RBCs and thawed plasmas were exchanged every fourth day and reintegrated into the blood bank inventory for further in-hospital use., Conclusions: Supplying HEMS with RBCs and plasma is feasible. Helicopter transport has no negative impact on blood product quality. The logistic challenges require close collaboration between the HEMS team and the blood transfusion service., Competing Interests: M.B. and K.-C.T. are members of the scientific working group of the DRF Luftrettung. M.R., F.R., J.B. are employees of the DRF Luftrettung. K.S. received research funding from Immucor, traveling support from SOBI and consultant fees from Aspen. A.G. received research funding from Ergomed, Boehringer Ingelheim, Rovi, Sagent, Macopharma, Portola, Biokit, Blau Farmaceutics, Prosensa/Biomarin, DRK-BSD NSTOB, DRK-BSD Baden-Württemberg/Hessen, travel support, speakers and consulting fees from Roche, GTH e.V., Sanofi-Aventis, Macopharma, Chromatec, Instrumentation Laboratory, Bayer Vital and Aspen. B.H., G.J., M.H., T.W., K.H. declare no conflict of interest., (Copyright © 2021 by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
9. 10 Years of Experience with the First Thawed Plasma Bank in Germany.
- Author
-
Selleng K and Greinacher A
- Abstract
Background: Plasma is stored at -30°C, which requires thawing before transfusion, causing a time delay between ordering and issuing of at least 30 min. In case of bleeding emergencies, guidelines strongly recommend a 2:1 transfusion ratio of RBCs and plasma. In addition, each minute delay in issuing of blood products in bleeding emergencies increases the mortality risk. To provide plasma in time in bleeding emergencies, a thawed plasma bank was introduced in 2011., Summary: The thawed plasma bank of University Medicine Greifswald has provided 18,924 thawed stored plasma units between 2011 and 2020. The workflow in the laboratory as well as in the emergency room, the operating room, and the intensive care unit have been optimized by thawed stored plasma. In case of emergencies, the stress factor for the transfusion medicine laboratory staff has been reduced substantially. The thawed plasma bank allows to transfuse patients with massive transfusion demand at a 2:1 ratio of RBCs and plasma according to guidelines. To reduce storage time, we issue all plasma requests from the thawed plasma bank except for pediatric patients. This results in a median storage time in the thawed plasma bank of 24 h. The "just in time" availability of plasma within the entire hospital based on the thawed plasma bank has reduced precautionary ordering of plasma, and hereby the unnecessary use of plasma. After introduction of the thawed plasma bank, plasma usage decreased substantially by 24% within the first year and by 60% compared to 2019/2020. However, as the overall approach to using blood products has changed over the last 10 years due to the patient blood management initiative, quantification of the effects of the thawed plasma bank in reduction of plasma transfusion is difficult., Key Messages: (1) A thawed plasma bank for the routine supply of blood products in a large hospital is feasible in Germany. (2) The thawed plasma bank allows to supply RBCs and plasma in a 2:1 ratio in bleeding emergencies. (3) The beneficial logistical effects of the thawed plasma bank are optimal if all plasma requests are supplied from the thawed plasma bank. This results in a median storage time of 24 h for thawed plasma., Competing Interests: K. Selleng received research funding from Immucor, traveling support from SOBI, and consultant fees from Aspen outside the submitted work. A. Greinacher reports grants and nonfinancial support from Aspen, Boehringer Ingelheim, MSD, Bristol Myers Squibb, Bayer Healthcare, Instrumentation Laboratory; personal fees from Aspen, MSD, Macopharma, Bristol Myers Squibb, Chromatec, Instrumentation Laboratory; and nonfinancial support from Portola, Ergomed, and Biokit outside the submitted work., (Copyright © 2021 by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
10. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.
- Author
-
Greinacher A, Selleng K, Mayerle J, Palankar R, Wesche J, Reiche S, Aebischer A, Warkentin TE, Muenchhoff M, Hellmuth JC, Keppler OT, Duerschmied D, Lother A, Rieg S, Gawaz MP, Mueller KAL, Scheer CS, Napp M, Hahnenkamp K, Lucchese G, Vogelgesang A, Flöel A, Lovreglio P, Stufano A, Marschalek R, and Thiele T
- Subjects
- Adult, Aged, Aged, 80 and over, Blood Platelets immunology, COVID-19 immunology, Cohort Studies, Epitopes immunology, Female, Heparin metabolism, Humans, Immunoglobulin G immunology, Male, Middle Aged, Protein Binding, Protein Domains, Purpura, Thrombocytopenic, Idiopathic blood, Spike Glycoprotein, Coronavirus chemistry, Young Adult, Antibodies adverse effects, COVID-19 Vaccines adverse effects, Cross Reactions immunology, Platelet Factor 4 immunology, Purpura, Thrombocytopenic, Idiopathic etiology, Purpura, Thrombocytopenic, Idiopathic immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associated with unusual thrombosis. VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets through their FcγRIIa receptors. Antibodies that activate platelets through FcγRIIa receptors have also been identified in patients with COVID-19. These findings raise concern that vaccination-induced antibodies against anti-SARS-CoV-2 spike protein cause thrombosis by cross-reacting with PF4. Immunogenic epitopes of PF4 and SARS-CoV-2 spike protein were compared using in silico prediction tools and 3D modeling. The SARS-CoV-2 spike protein and PF4 share at least 1 similar epitope. Reactivity of purified anti-PF4 antibodies from patients with VITT was tested against recombinant SARS-CoV-2 spike protein. However, none of the affinity-purified anti-PF4 antibodies from 14 patients with VITT cross-reacted with SARS-CoV-2 spike protein. Sera from 222 polymerase chain reaction-confirmed patients with COVID-19 from 5 European centers were tested by PF4-heparin enzyme-linked immunosorbent assays and PF4-dependent platelet activation assays. We found anti-PF4 antibodies in sera from 19 (8.6%) of 222 patients with COVID-19. However, only 4 showed weak to moderate platelet activation in the presence of PF4, and none of those patients developed thrombotic complications. Among 10 (4.5%) of 222 patients who had COVID-19 with thrombosis, none showed PF4-dependent platelet-activating antibodies. In conclusion, antibodies against PF4 induced by vaccination do not cross-react with the SARS-CoV-2 spike protein, indicating that the intended vaccine-induced immune response against SARS-CoV-2 spike protein is not the trigger of VITT. PF4-reactive antibodies found in patients with COVID-19 in this study were not associated with thrombotic complications., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
11. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
- Author
-
Thiele T, Ulm L, Holtfreter S, Schönborn L, Kuhn SO, Scheer C, Warkentin TE, Bröker BM, Becker K, Aurich K, Selleng K, Hübner NO, and Greinacher A
- Subjects
- Adult, Asymptomatic Diseases, Autoantibodies blood, BNT162 Vaccine, ChAdOx1 nCoV-19, Female, Health Personnel, Humans, Immunoenzyme Techniques, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Middle Aged, Platelet Activation, Purpura, Thrombotic Thrombocytopenic immunology, Seroconversion, Thrombophilia etiology, Autoantibodies immunology, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Platelet Factor 4 immunology, Polyelectrolytes, Purpura, Thrombotic Thrombocytopenic etiology, Vaccination adverse effects
- Abstract
Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia (VITT). Affected patients test strongly positive in platelet factor 4 (PF4)/polyanion enzyme immunoassays (EIAs), and serum-induced platelet activation is maximal in the presence of PF4. We determined the frequency of anti-PF4/polyanion antibodies in healthy vaccinees and assessed whether PF4/polyanion EIA+ sera exhibit platelet-activating properties after vaccination with ChAdOx1 nCoV-19 (n = 138) or BNT162b2 (BioNTech/Pfizer; n = 143). In total, 19 of 281 participants tested positive for anti-PF4/polyanion antibodies postvaccination (All: 6.8% [95% confidence interval (CI), 4.4-10.3]; BNT162b2: 5.6% [95% CI, 2.9-10.7]; ChAdOx1 nCoV-19: 8.0% [95% CI, 4.5% to 13.7%]). Optical densities were mostly low (between 0.5 and 1.0 units; reference range, <0.50), and none of the PF4/polyanion EIA+ samples induced platelet activation in the presence of PF4. We conclude that positive PF4/polyanion EIAs can occur after severe acute respiratory syndrome coronavirus 2 vaccination with both messenger RNA- and adenoviral vector-based vaccines, but many of these antibodies likely have minor (if any) clinical relevance. Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against COVID-19. Pathogenic platelet-activating antibodies that cause VITT do not occur commonly following vaccination., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
12. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses.
- Author
-
Solves P, Lozano M, Zhiburt E, Anguita Velasco J, Maria Pérez-Corral A, Monsalvo-Saornil S, Yamazaki S, Okazaki H, Selleng K, Aurich K, Krüger W, Buser A, Holbro A, Infanti L, Stehle G, Pierelli L, Matteocci A, Rigacci L, De Vooght KMK, Kuball JHE, Fielding KL, Westerman DA, Wood EM, Cohn CS, Johnson A, Koh MBC, Qadir D, Cserti-Gazdewich C, Daguindau E, Angelot-Delettre F, Tiberghien P, Wendel-Neto S, Fachini RM, Morton S, Craddock C, Lumley M, Antoniewicz-Papis J, Hałaburda K, Łętowska M, and Dunbar N
- Published
- 2021
- Full Text
- View/download PDF
13. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Summary.
- Author
-
Solves P, Lozano M, Zhiburt E, Anguita Velasco J, Maria Pérez-Corral A, Monsalvo-Saornil S, Yamazaki S, Okazaki H, Selleng K, Aurich K, Krüger W, Buser A, Holbro A, Infanti L, Stehle G, Pierelli L, Matteocci A, Rigacci L, De Vooght KMK, Kuball JHE, Fielding KL, Westerman DA, Wood EM, Cohn CS, Johnson A, Koh MBC, Qadir D, Cserti-Gazdewich C, Daguindau E, Angelot-Delettre F, Tiberghien P, Wendel-Neto S, Fachini RM, Morton S, Craddock C, Lumley M, Antoniewicz-Papis J, Hałaburda K, Łętowska M, and Dunbar N
- Published
- 2021
- Full Text
- View/download PDF
14. Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G.
- Author
-
Raster J, Zimmermann K, Wesche J, Aurich K, Greinacher A, and Selleng K
- Abstract
Introduction: In the light of the ongoing SARS-CoV-2 pandemic, convalescent plasma is a treatment option for CO-VID-19. In contrast to usual therapeutic plasma, the therapeutic agents of convalescent plasma do not represent clotting factor activities, but immunoglobulins. Quarantine storage of convalescent plasma as a measure to reduce the risk of pathogen transmission is not feasible. Therefore, pathogen inactivation (e.g., Theraflex®-MB, Macopharma, Mouvaux, France) is an attractive option. Data on the impact of pathogen inactivation by methylene blue (MB) treatment on antibody integrity are sparse., Methods: Antigen-specific binding capacity was tested before and after MB treatment of plasma ( n = 10). IgG and IgM isoagglutinin titers were tested by agglutination in increasing dilutions. Furthermore, the binding of anti-EBV and anti-tetanus toxin IgG to their specific antigens was assessed by ELISA, and IgG binding to Fc receptors was assessed by flow cytometry using THP-1 cells expressing FcRI and FcRII., Results: There was no significant difference in the isoagglutinin titers, the antigen binding capacity of anti-EBV and anti-tetanus toxin IgG, as well as the Fc receptor binding capacity before and after MB treatment of plasma., Conclusion: MB treatment of plasma does not inhibit the binding capacity of IgM and IgG to their epitopes, or the Fc receptor interaction of IgG. Based on these results, MB treatment of convalescent plasma is appropriate to reduce the risk of pathogen transmission if quarantine storage is omitted., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2021 by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
15. Red-blood-cell alloimmunization and prophylactic antigen matching for transfusion in patients with warm autoantibodies.
- Author
-
Delaney M, Apelseth TO, Bonet Bub C, Cohn CS, Dunbar NM, Mauro Kutner J, Murphy M, Perelman I, Selleng K, Staves J, Wendel S, and Ziman A
- Subjects
- Adult, Anemia, Hemolytic, Autoimmune etiology, Blood Transfusion, Autologous adverse effects, Erythrocytes immunology, Female, Humans, Male, Anemia, Hemolytic, Autoimmune epidemiology, Autoantibodies immunology, Blood Transfusion, Autologous methods
- Abstract
Background: Warm autoantibodies (WAA) are antibodies that react with an antigen on a patient's own red-blood-cells and can complicate compatibility testing whether or not they cause clinical haemolysis. The goal of this study was to understand the overall prevalence of WAA, the risk of RBC alloimmunization and determine whether RBC selection practices have an impact on alloimmunization., Materials and Methods: Records of patients (>1 year of age) with an indirect antibody detection test (IAT) and serologic evidence of WAA over a 10-year-period were included. Eight centres from 5 countries collectively reviewed 1 122 245 patients who had an IAT., Results: Of patients having IAT, 1214 had WAA (0·17%). Transfusion information for 1002 of the patients was available; 631 were transfused after identification of the WAA (63%); of the transfused patients, 390 received prophylactic antigen-matched (PAM) RBCs and 241 did not. Of the 372 patients with WAA who were transfused and had serologic testing 30+ days following transfusion (30-2765 days), 56 developed new RBC alloimmunization (15·1%). Patients who were transfused using a PAM strategy were not protected from new RBC alloimmunization [14·6% (31 of 212 patients) having PAM transfusion approach compared with those not receiving PAM approach (15·6%, 25 of 160 patients, P = 0·8837)]., Conclusions: The prevalence of WAA in patients having an IAT is low (<1%). A significant portion of patients with WAA form new RBC alloimmunization (15·1%); however, the use of PAM approach for RBC selection was not found to be protective against new alloimmunization., (© 2020 International Society of Blood Transfusion.)
- Published
- 2020
- Full Text
- View/download PDF
16. Electronic patient identification for sample labeling reduces wrong blood in tube errors.
- Author
-
Kaufman RM, Dinh A, Cohn CS, Fung MK, Gorlin J, Melanson S, Murphy MF, Ziman A, Elahie AL, Chasse D, Degree L, Dunbar NM, Dzik WH, Flanagan P, Gabert K, Ipe TS, Jackson B, Lane D, Raspollini E, Ray C, Sharon Y, Ellis M, Selleng K, Staves J, Yu P, Zeller M, and Yazer M
- Subjects
- Blood Banks statistics & numerical data, Blood Specimen Collection standards, Humans, Retrospective Studies, Electronic Health Records standards, Medical Errors statistics & numerical data
- Abstract
Background: Wrong blood in tube (WBIT) errors are a preventable cause of ABO-mismatched RBC transfusions. Electronic patient identification systems (e.g., scanning a patient's wristband barcode before pretransfusion sample collection) are thought to reduce WBIT errors, but the effectiveness of these systems is unclear., Study Design and Methods: Part 1: Using retrospective data, we compared pretransfusion sample WBIT rates at hospitals using manual patient identification (n = 16 sites; >1.6 million samples) with WBIT rates at hospitals using electronic patient identification for some or all sample collections (n = 4 sites; >0.5 million samples). Also, we compared WBIT rates after implementation of electronic patient identification with preimplementation WBIT rates. Causes and frequencies of WBIT errors were evaluated at each site. Part 2: Transfusion service laboratories (n = 18) prospectively typed mislabeled (rejected) samples (n = 2844) to determine WBIT rates among samples with minor labeling errors., Results: Part 1: The overall unadjusted WBIT rate at sites using manual patient identification was 1:10,110 versus 1:35,806 for sites using electronic identification (p < 0.0001). Correcting for repeat samples and silent WBIT errors yielded overall adjusted WBIT rates of 1:3046 for sites using manual identification and 1:14,606 for sites using electronic identification (p < 0.0001), with wide variation among individual sites. Part 2: The unadjusted WBIT rate among mislabeled (rejected) samples was 1:71 (adjusted WBIT rate, 1:28)., Conclusion: In this study, using electronic patient identification at the time of pretransfusion sample collection was associated with approximately fivefold fewer WBIT errors compared with using manual patient identification. WBIT rates were high among mislabeled (rejected) samples, confirming that rejecting samples with even minor labeling errors helps mitigate the risk of ABO-incompatible transfusions., (© 2018 AABB.)
- Published
- 2019
- Full Text
- View/download PDF
17. F(ab') 2 Fragments to Overcome Daratumumab Interference in Transfusion Tests.
- Author
-
Selleng K, Gebicka PD, and Thiele T
- Subjects
- ADP-ribosyl Cyclase 1, Cross Reactions drug effects, Histocompatibility Testing, Humans, Membrane Glycoproteins, Antibodies, Monoclonal pharmacology, Coombs Test, Immunoglobulin Fab Fragments pharmacology
- Published
- 2018
- Full Text
- View/download PDF
18. International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy.
- Author
-
De Vooght KMK, Lozano M, Bueno JL, Alarcón A, Romera I, Suzuki K, Zhiburt E, Holbro A, Infanti L, Buser A, Hustinx H, Deneys V, Frélik A, Thiry C, Murphy M, Staves J, Selleng K, Greinacher A, Kutner JM, Bonet Bub C, Castilho L, Kaufman RM, Colling ME, Perseghin P, Incontri A, Dassi M, Brilhante D, Macédo A, Cserti-Gazdewich C, Pendergrast JM, Hawes J, Lundgren MN, Storry JR, Jain A, Marwaha N, and Sharma RR
- Published
- 2018
- Full Text
- View/download PDF
19. Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary.
- Author
-
de Vooght KMK, Lozano M, Bueno JL, Alarcón A, Romera I, Suzuki K, Zhiburt E, Holbro A, Infanti L, Buser A, Hustinx H, Deneys V, Frélik A, Thiry C, Murphy M, Staves J, Selleng K, Greinacher A, Kutner JM, Bonet Bub C, Castilho L, Kaufman R, Colling ME, Perseghin P, Incontri A, Dassi M, Brilhante D, Macêdo A, Cserti-Gazdewich C, Pendergrast JM, Hawes J, Lundgren MN, Storry JR, Jain A, Marwaha N, and Sharma RR
- Published
- 2018
- Full Text
- View/download PDF
20. Autoimmune heparin-induced thrombocytopenia.
- Author
-
Greinacher A, Selleng K, and Warkentin TE
- Subjects
- Administration, Oral, Animals, Anticoagulants administration & dosage, Anticoagulants immunology, Blood Coagulation drug effects, Blood Platelets immunology, Blood Platelets metabolism, Heparin immunology, Humans, Immunoglobulins, Intravenous administration & dosage, Immunologic Factors administration & dosage, Partial Thromboplastin Time, Platelet Activation drug effects, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic drug therapy, Purpura, Thrombocytopenic, Idiopathic immunology, Anticoagulants adverse effects, Autoantibodies blood, Autoimmunity drug effects, Blood Platelets drug effects, Heparin adverse effects, Platelet Factor 4 immunology, Purpura, Thrombocytopenic, Idiopathic chemically induced
- Abstract
Autoimmune heparin-induced thrombocytopenia (aHIT) indicates the presence in patients of anti-platelet factor 4 (PF4)-polyanion antibodies that are able to activate platelets strongly even in the absence of heparin (heparin-independent platelet activation). Nevertheless, as seen with serum obtained from patients with otherwise typical heparin-induced thrombocytopenia (HIT), serum-induced platelet activation is inhibited at high heparin concentrations (10-100 IU mL
-1 heparin). Furthermore, upon serial dilution, aHIT serum will usually show heparin-dependent platelet activation. Clinical syndromes associated with aHIT include: delayed-onset HIT, persisting HIT, spontaneous HIT syndrome, fondaparinux-associated HIT, heparin 'flush'-induced HIT, and severe HIT (platelet count of < 20 × 109 L-1 ) with associated disseminated intravascular coagulation (DIC). Recent studies have implicated anti-PF4 antibodies that are able to bridge two PF4 tetramers even in the absence of heparin, probably facilitated by non-heparin platelet-associated polyanions (chondroitin sulfate and polyphosphates); nascent PF4-aHIT-IgG complexes recruit additional heparin-dependent HIT antibodies, leading to the formation of large multimolecular immune complexes and marked platelet activation. aHIT can persist for several weeks, and serial fibrin, D-dimer, and fibrinogen levels, rather than the platelet count, may be helpful for monitoring treatment response. Although standard anticoagulant therapy for HIT ought to be effective, published experience indicates frequent failure of activated partial thromboplastin time (APTT)-adjusted anticoagulants (argatroban, bivalirudin), probably because of underdosing in the setting of HIT-associated DIC, known as 'APTT confounding'. Thus, non-APTT-adjusted therapies with drugs such as danaparoid and fondaparinux, or even direct oral anticoagulants, such as rivaroxaban or apixaban, are suggested therapies, especially for long-term management of persisting HIT. In addition, emerging data indicate that high-dose intravenous immunoglobulin can interrupt HIT antibody-induced platelet activation, leading to rapid platelet count recovery., (© 2017 International Society on Thrombosis and Haemostasis.)- Published
- 2017
- Full Text
- View/download PDF
21. An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study.
- Author
-
Zeller MP, Barty R, Aandahl A, Apelseth TO, Callum J, Dunbar NM, Elahie A, Garritsen H, Hancock H, Kutner JM, Manukian B, Mizuta S, Okuda M, Pagano MB, Pogłód R, Rushford K, Selleng K, Sørensen CH, Sprogøe U, Staves J, Weiland T, Wendel S, Wood EM, van de Watering L, van Wordragen-Vlaswinkel M, Ziman A, Jan Zwaginga J, Murphy MF, Heddle NM, and Yazer MH
- Subjects
- ABO Blood-Group System immunology, Blood Group Incompatibility, Hospitals, Humans, Retrospective Studies, Rh-Hr Blood-Group System immunology, Surveys and Questionnaires, Erythrocyte Transfusion statistics & numerical data, Erythrocytes immunology
- Abstract
Background: Transfusion of group O blood to non-O recipients, or transfusion of D- blood to D+ recipients, can result in shortages of group O or D- blood, respectively. This study investigated RBC utilization patterns at hospitals around the world and explored the context and policies that guide ABO blood group and D type selection practices., Study Design and Methods: This was a retrospective study on transfusion data from the 2013 calendar year. This study included a survey component that asked about hospital RBC selection and transfusion practices and a data collection component where participants submitted information on RBC unit disposition including blood group and D type of unit and recipient. Units administered to recipients of unknown ABO or D group were excluded., Results: Thirty-eight hospitals in 11 countries responded to the survey, 30 of which provided specific RBC unit disposition data. Overall, 11.1% (21,235/191,397) of group O units were transfused to non-O recipients; 22.6% (8777/38,911) of group O D- RBC units were transfused to O D+ recipients, and 43.2% (16,800/38,911) of group O D- RBC units were transfused to recipients that were not group O D-. Disposition of units and hospital transfusion policy varied within and across hospitals of different sizes, with transfusion of group O D- units to non-group O D- patients ranging from 0% to 33%., Conclusion: A significant proportion of group O and D- RBC units were transfused to compatible, nonidentical recipients, although the frequency of this practice varied across sites., (© 2017 AABB.)
- Published
- 2017
- Full Text
- View/download PDF
22. Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information.
- Author
-
Yazer MH, van de Watering L, Lozano M, Sirdesai S, Rushford K, Wood EM, Yokoyama AP, Kutner JM, Lin Y, Callum J, Cserti-Gazdewich C, Lieberman L, Pendergrast J, Pendry K, Murphy MF, Selleng K, Greinacher A, Marwaha N, Sharma R, Jain A, Orlin Y, Yahalom V, Perseghin P, Incontri A, Masera N, Okazaki H, Ikeda T, Nagura Y, Zwaginga JJ, Pogłod R, Rosiek A, Letowska M, Yuen J, Cid J, Harm SK, and Adhikari P
- Published
- 2017
- Full Text
- View/download PDF
23. [Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
- Author
-
Wernicke S, Selleng K, Felix SB, Greinacher A, and Hammer F
- Subjects
- Anticoagulants therapeutic use, Antiphospholipid Syndrome blood, Antiphospholipid Syndrome drug therapy, Antiphospholipid Syndrome etiology, Female, Humans, International Normalized Ratio, Lupus Erythematosus, Systemic complications, Partial Thromboplastin Time, Pulmonary Embolism blood, Pulmonary Embolism drug therapy, Recurrence, Thromboembolism prevention & control, Venous Thrombosis complications, Antithrombins therapeutic use, Dabigatran therapeutic use, Pulmonary Embolism etiology
- Abstract
We report on a female patient with confirmed secondary antiphospholipid syndrome (APS) due to underlying systemic lupus erythematosus (SLE). Despite a thromboplastin time within the normal range (international normalized ratio, INR) under treatment with a vitamin K antagonist (VKA), a recurrent thrombotic event occurred, this time as pulmonary embolism due to bilateral deep vein thrombosis. Despite an INR value in the therapeutic range, clotting factors II, VII, IX and X were found to be insufficiently decreased suggesting inefficient anticoagulation. Thus, the anticoagulation regimen was changed to the direct oral anticoagulant dabigatran. This case demonstrates that the INR in APS patients may be artificially prolonged in rare cases, despite a normal activated partial thromboplastin time (aPTT) and cannot be used for monitoring VKA anticoagulant therapy. Suspicion of ineffective anticoagulation despite VKA therapy should prompt measurement of the individual clotting factors.
- Published
- 2017
- Full Text
- View/download PDF
24. Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information: summary.
- Author
-
Yazer MH, van de Watering L, Lozano M, Sirdesai S, Rushford K, Wood EM, Yokoyama AP, Kutner JM, Lin Y, Callum J, Cserti-Gazdewich C, Lieberman L, Pendergrast J, Pendry K, Murphy MF, Selleng K, Greinacher A, Marwaha N, Sharma R, Jain A, Orlin Y, Yahalom V, Perseghin P, Incontri A, Masera N, Okazaki H, Ikeda T, Nagura Y, Zwaginga JJ, Pogłod R, Rosiek A, Letowska M, Yuen J, Cid J, Harm SK, and Adhikari P
- Published
- 2017
- Full Text
- View/download PDF
25. Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study.
- Author
-
Selleng K, Jenichen G, Denker K, Selleng S, Müllejans B, and Greinacher A
- Subjects
- Aged, Blood Group Antigens immunology, Blood Transfusion mortality, Coombs Test methods, Emergency Treatment, Feasibility Studies, Female, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Prospective Studies, Rho(D) Immune Globulin therapeutic use, Blood Transfusion methods, Erythrocyte Transfusion methods, Erythrocytes physiology, Rho(D) Immune Globulin immunology
- Abstract
Background: Emergency patients with unknown blood type usually receive O Rhesus D negative (RhD-) red blood cell concentrates until their blood group is determined to prevent RhD+ related adverse transfusion reactions. As 85% of individuals are RhD+, this consumption of O RhD- red blood cell concentrates contributes to shortages of O RhD- red blood cell concentrates, sometimes forcing transfusion of known RhD- patients with RhD+ red blood cell concentrates. Here we report the outcome of this transfusion policy transfusing all emergency patients with unknown blood type with O RhD+ red blood cell concentrates., Methods: In this prospective single-centre observational study done between Jan 1, 2001, and Dec 31, 2015, we assessed all consecutive RhD- patients at the University Medicine Greifswald who received RhD+ red blood cell concentrates (emergency patients with unknown blood type; and RhD- patients receiving RhD+ red blood cell concentrates during RhD- red blood cell concentrate shortages). No patients were excluded. The primary endpoint was anti-D allo-immunisation at 2 months follow-up or later. Patients were followed up and tested for immunisation against red blood cell antigens using the direct antiglobulin test and an antibody screen every 3-5 days for 4 weeks or until death, or hospital discharge. Surviving patients were screened for development of anti-D antibodies for up to 12 months (at the predefined timepoints 2, 3, 6, and 12 months) after RhD+ red blood cell transfusion., Findings: 437 emergency patients, of whom 85 (20%) were RhD-, received 2836 RhD+ red blood cell concentrates. The overall risk of inducing anti-D antibodies (in all 437 recipients) was 17 (4%, 95% CI 2·44-6·14) of 437 (assuming all patients lost to follow-up developed anti-D allo-immunisation). During this period, 110 known RhD- patients received RhD+ red blood cell concentrates during RhD- red blood cell concentrate shortages. Of these, 29 (26%; 95% CI 19·0-35·3) developed anti-D allo-immunisation (assuming all patients lost to follow-up developed anti-D), which was significantly higher than in the emergency patients with unknown blood type (p<0·0001)., Interpretation: Transfusing emergency patients with unknown blood type with O RhD+ red blood cell concentrates has a low risk of inducing anti-D antibodies (3-6%), but saves more than 10% of the total O RhD- red blood cell concentrate demand, thereby reducing shortage of O RhD- red blood cell concentrates, the need to transfuse known RhD-patients with RhD+ red blood cell concentrates, and thus the overall risk to induce anti-D allo-immunisation in the population. These findings should be considered for transfusion guidelines., Funding: University Medicine Greifswald., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
26. An international survey on the role of the hospital transfusion committee.
- Author
-
Yazer MH, Lozano M, Fung M, Kutner J, Murphy MF, Oveland Apelseth T, Pogłód R, Selleng K, Tinmouth A, Wendel S, and Yahalom V
- Subjects
- Blood Transfusion statistics & numerical data, Hospitals, University, Humans, Internationality, Product Labeling, Quality of Health Care, Surveys and Questionnaires, Workforce, Blood Transfusion standards, Professional Staff Committees standards, Quality Assurance, Health Care methods, Transfusion Medicine standards
- Abstract
Background: Hospital transfusion committees (HTCs) can oversee all aspects of transfusion practice at a hospital. This survey sought to identify which quality variables were being reported at HTCs around the world., Study Design and Methods: A working party composed of members of the Biomedical Excellence for Safer Transfusion (BEST) collaborative developed a survey of quality variables that could be potentially presented at HTC meetings. The survey was electronically sent to all BEST members who were encouraged to complete it if they were active on an HTC and to send it to other colleagues with similar experience. An expert panel was convened to determine which quality variables are the most important for review at HTC meetings., Results: There were 121 respondents; the majority were from Europe (52%), Asia (19%), or North America (19%). Most respondents (68%) were at university hospitals. Of the 117 (97%) respondents with an HTC, the committee most often met quarterly (42%) and reviewed transfusion reactions (79%) and risk management-reported events (52%). The HTCs most commonly included transfusion medicine physicians, anesthesiologists, and other physicians who regularly transfuse blood products. Some of the most commonly reported quality variables included number of blood products transfused, wasted, and expired and the number of improperly labeled specimens. The expert panel analysis revealed that some variables that were deemed important were not being frequently reported at HTCs., Conclusion: There is variability in the variables being reported at HTCs around the world with some important variables not frequently reported., (© 2017 AABB.)
- Published
- 2017
- Full Text
- View/download PDF
27. Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients.
- Author
-
Selleng S and Selleng K
- Subjects
- Anticoagulants therapeutic use, Critical Illness, Humans, Thrombocytopenia chemically induced, Cardiac Surgical Procedures, Heparin adverse effects, Thrombocytopenia surgery
- Abstract
Thrombocytopenia as well as anti-platelet factor 4/heparin (PF4/H) antibodies are common in cardiac surgery patients and those treated in the intensive care unit. In contrast, heparin-induced thrombocytopenia (HIT) is uncommon in these populations (~1 % and ~0.5 %, respectively). A stepwise approach where testing for anti-PF4/H antibodies is performed only in patients with typical clinical symptoms of HIT improves diagnostic specificity of the laboratory assays without losing sensitivity, thereby helping to avoid overdiagnosis and resulting HIT overtreatment. Short-term re-exposure to heparin, especially given intraoperatively for cardiovascular surgery, is a reasonable therapeutic option in patients with a history of HIT who subsequently test negative for HIT antibodies. Organ failure(s), enhanced bleeding risks, and other characteristics require special considerations regarding non-heparin anticoagulation: Argatroban is the alternative anticoagulant with pharmacokinetics independent of renal function, but it has a prolonged half-life in case of impaired liver function. For bivalirudin, protocols during cardiopulmonary bypass surgery are established, and it is suitable for patients with liver insufficiency. A major issue of direct thrombin inhibitors are false high activated partial thromboplastin time values in patients with comorbidities affecting prothrombin, which can result in systematic underdosing of the drugs. This is not the case for danaparoid and fondaparinux, which can be monitored by anti-factor Xa assays, but have long half-lives and no suitable antidote. This review includes also information on management of on- and off-pump cardiac surgery, ventricular assist devices, percutaneous interventions, continuous renal replacement therapy, and extracorporeal membrane oxygenation in patients with HIT.
- Published
- 2016
- Full Text
- View/download PDF
28. Survival after ultramassive transfusion: a review of 1360 cases.
- Author
-
Dzik WS, Ziman A, Cohn C, Pai M, Lozano M, Kaufman RM, Delaney M, Selleng K, Murphy MF, Hervig T, and Yazer M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Erythrocyte Transfusion statistics & numerical data, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Transplants statistics & numerical data, Wounds and Injuries mortality, Wounds and Injuries therapy, Young Adult, Blood Transfusion statistics & numerical data
- Abstract
Background: Information about patient survival after transfusion of multiple blood volumes is limited, and most reports have focused on trauma patients., Study Design and Methods: Retrospective study of blood use and survival at 11 hospitals in six nations between 2009 and 2013. Ultramassive transfusion (UMT) was defined as transfusion of 20 or more red blood cell (RBC) units over the course of any 2 consecutive calendar days., Results: A total of 1975 patients received UMT and a representative sample of 1360 patients was studied in detail. Patients were grouped into seven diagnostic categories: solid organ transplantation (n = 411), cardiac or major vascular surgery (n = 317), general surgery (n = 228), trauma (n = 221), general medicine (n = 124), obstetrics (n = 23), and other (n = 36). During the 7 days after initiation of UMT, these patients used more than 120,000 blood components. The median (interquartile range) blood use was 35 (26-50) RBC units, 30 (20-47) plasma units, and 7 (4-13) platelet doses. Five- and 30-day survival significantly declined with increasing RBC use. Overall survivals of patients receiving UMT were 71% (5 day) and 60% (30 day), and in the subset of 165 patients receiving 60 or more RBC units over 2 consecutive days, 5-day survival was 54% ranging from 17% (trauma) to 75% (solid organ transplant). The decline in survival with increasing RBC transfusions was minimal for patients undergoing solid organ transplantation and was most pronounced for trauma and nonsurgical bleeding patients., Conclusion: Trauma was not the leading cause of UMT. Increasing RBC requirements were significantly associated with decreasing survival. However, survival was more strongly associated with diagnostic category than total RBCs transfused, with highest survival rates in solid organ transplant surgery., (© 2015 AABB.)
- Published
- 2016
- Full Text
- View/download PDF
29. Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation.
- Author
-
Thiele T, Hron G, Kellner S, Wasner C, Westphal A, Warkentin TE, Greinacher A, and Selleng K
- Subjects
- Blood Coagulation Tests, Cryopreservation methods, Humans, Light, Plasma drug effects, Plasma radiation effects, Protein C metabolism, Blood Preservation methods, Methylene Blue pharmacology, Partial Thromboplastin Time, Plasma metabolism, Prothrombin Time, Sterilization methods, Thrombin metabolism
- Abstract
Background: Methylene blue pathogen inactivation and storage of thawed plasma both lead to changes in the activity of several clotting factors. We investigated how this translates into a global loss of thrombin generation potential and alterations in the protein C pathway., Materials and Methods: Fifty apheresis plasma samples were thawed and each divided into three subunits. One subunit was stored for 7 days at 4 °C, one was stored for 7 days at 22 °C and one was stored at 4 °C after methylene blue/light treatment. Thrombin generation parameters, ProC(®)Global-NR, prothrombin time and activated partial thromboplastin time were assessed on days 0 and 7., Results: The velocity of thrombin generation increased significantly after methylene blue treatment (increased thrombin generation rate; time to peak decreased) and decreased after storage (decreased thrombin generation rate and peak thrombin; increased lag time and time to peak). The endogenous thrombin generation potential remained stable after methylene blue treatment and storage at 4 °C. Methylene blue treatment and 7 days of storage at 4 °C activated the protein C pathway, whereas storage at room temperature and storage after methylene blue treatment decreased the functional capacity of the protein C pathway. Prothrombin time and activated partial thromboplastin time showed only modest alterations., Discussion: The global clotting capacity of thawed plasma is maintained at 4 °C for 7 days and directly after methylene blue treatment of thawed plasma. Thrombin generation and ProC(®)Global are useful tools for investigating the impact of pathogen inactivation and storage on the clotting capacity of therapeutic plasma preparations.
- Published
- 2016
- Full Text
- View/download PDF
30. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction--a phase I clinical trial.
- Author
-
Thiele T, Pohler P, Kohlmann T, Sümnig A, Aurich K, Selleng K, Westphal A, Bakchoul T, Petersmann A, Müller TH, Greinacher A, and Seltsam A
- Subjects
- Adult, Blood Platelets drug effects, Fibrin Fibrinogen Degradation Products analysis, Healthy Volunteers, Humans, Immunoglobulin E blood, Male, Partial Thromboplastin Time, Photosensitizing Agents pharmacology, Platelet Count, Prothrombin Time, Young Adult, Blood Platelets radiation effects, Platelet Transfusion adverse effects, Ultraviolet Rays
- Abstract
Background: The THERAFLEX UV-Platelets pathogen reduction system for platelet concentrates (PCs) operates with ultraviolet C light (UVC; 254 nm) only without addition of photosensitizers. This phase I study evaluated safety and tolerability of autologous UVC-irradiated PCs in healthy volunteers., Methods: Eleven volunteers underwent two single (series 1 and 2) and one double apheresis (series 3). PCs were treated with UVC, stored for 48 h and retransfused in a dose-escalation scheme: 12·5, 25% and 50% of a PC (series 1); one complete PC (series 2); two PCs (series 3). Platelet counts, fibrinogen, activated partial thromboplastin time, prothrombin time, D-dimer, standard haematology, temperature, heart rate, blood pressure and clinical chemistry parameters were measured. One- and 24-h corrected count increments were determined in series 2 and 3. Platelet-specific antibodies were assessed before and at the end of the study., Results: Neither adverse reactions related to transfusions nor antibodies against UVC-treated platelets were observed. Corrected count increments did not differ between series 2 and 3., Conclusions: Repeated transfusions of autologous UVC-treated PCs were well tolerated and did not induce antibody responses in all volunteers studied. EudraCT No. 2010-023404-26., (© 2015 International Society of Blood Transfusion.)
- Published
- 2015
- Full Text
- View/download PDF
31. Reversal of anticoagulants: an overview of current developments.
- Author
-
Greinacher A, Thiele T, and Selleng K
- Subjects
- Administration, Oral, Animals, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Anticoagulants chemistry, Antithrombins therapeutic use, Benzamides therapeutic use, Clinical Trials as Topic, Dabigatran therapeutic use, Factor Xa therapeutic use, Fondaparinux, Hemorrhage chemically induced, Hemostatics chemistry, Heparin therapeutic use, Humans, Infusions, Parenteral, Intracranial Hemorrhages prevention & control, Polysaccharides therapeutic use, Protamines therapeutic use, Pyrazoles therapeutic use, Pyridines therapeutic use, Pyridones therapeutic use, Recombinant Proteins therapeutic use, Rivaroxaban therapeutic use, Thiazoles therapeutic use, Thrombosis complications, Thrombosis drug therapy, Vitamin K antagonists & inhibitors, Anticoagulants administration & dosage, Factor Xa Inhibitors therapeutic use, Hemorrhage prevention & control, Hemostatics therapeutic use
- Abstract
Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban), and the direct thrombin inhibitor dabigatran. Especially the oral direct FXa and FIIa inhibitors overcome many of the shortcomings of heparins and vitamin K antagonists (VKAs). They are administered orally at a fixed dose; regular monitoring is not necessary; interaction with other drugs or nutrition occur less than with VKAs and they are at least as effective as VKAs for most indications tested. They are associated with about 50 % less intracranial bleeding than VKAs. Nevertheless, they are still associated with bleeding complications. Bleeding can occur spontaneously or as a result of trauma or urgent surgery. In such situations rapid reversal of the anticoagulant effect is highly desirable. For unfractionated heparin protamine, and for VKAs prothrombin complex concentrates are available as specific antidotes. Under clinical development are: for the direct and indirect FXa inhibitors a modified recombinant FXa (andexanet alpha), which lacks enzymatic activity; and for dabigatran a Fab fragment of a monoclonal antibody (idarucizumab). In addition a small molecule (aripazine) has entered phase I clinical trials, which seems to inhibit nearly all anticoagulants but VKAs and argatroban. This review summarises the current options and strategies in development to antagonise anticoagulants with a focus on the status of the development of antidotes for the oral direct FXa and FIIa inhibitors.
- Published
- 2015
- Full Text
- View/download PDF
32. Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.
- Author
-
Selleng S, Selleng K, Friesecke S, Gründling M, Kuhn SO, Raschke R, Heidecke OJ, Hinz C, Hron G, Warkentin TE, and Greinacher A
- Subjects
- Aged, Female, Humans, Intensive Care Units, Male, Middle Aged, Platelet Count, Prospective Studies, Anticoagulants administration & dosage, Anticoagulants adverse effects, Anticoagulants immunology, Autoantibodies blood, Autoantibodies immunology, Heparin administration & dosage, Heparin adverse effects, Heparin immunology, Platelet Activation drug effects, Platelet Activation immunology, Platelet Factor 4 blood, Platelet Factor 4 immunology, Thrombocytopenia blood, Thrombocytopenia chemically induced, Thrombocytopenia epidemiology, Thrombocytopenia immunology, Thrombocytopenia pathology
- Abstract
Data on the frequency of anti-platelet factor 4/heparin (PF4/H) antibodies and their association with outcomes in intensive care unit (ICU) patients are sparse. In this prospective, observational study we screened 320 consecutive surgical/medical ICU patients for anti-PF4/H antibodies by enzyme-immunoassay (EIA) for immunoglobulin (Ig)G/A/M separately and heparin-induced platelet activation assay (HIPA) at ICU admission (=baseline), day 6, and day 10. HIPA-positive patients were additionally tested by serotonin-release assay (SRA). Patients tested positive by day 10: for anti-PF4/H-IgG = 17.2 % and for anti-PF4/H-IgM = 42.1 %. Within the first 10 ICU days, platelet counts decreased to <100 Gpt/L in 27.8 % patients. However, only seven patients (2.2 %) experienced a drop in the platelet count ≥50 % beginning after the fourth ICU day. These included the only two patients (0.6 %; 95 % confidence interval 0.08-2.2 %) with heparin-induced thrombocytopenia (HIT). Only strong reactions in the HIPA were reproducible by SRA. This study confirms that testing for anti-PF4/H IgG antibodies should be restricted to ICU-patients who develop a platelet count decrease of >50 % that begins after day four of heparin treatment (which may have started before ICU admission). Among patients testing positive by IgG-specific EIA a functional platelet activation assay should be performed (regarding only strong reactions as positive).
- Published
- 2015
- Full Text
- View/download PDF
33. Thrombocytopenia in the intensive care unit-diagnostic approach and management.
- Author
-
Thiele T, Selleng K, Selleng S, Greinacher A, and Bakchoul T
- Subjects
- Critical Illness, Hemorrhage complications, Hemorrhage etiology, Humans, Intensive Care Units, Platelet Count, Platelet Transfusion adverse effects, Postoperative Complications, Thrombocytopenia diagnosis, Thrombocytopenia etiology, Thrombocytopenia therapy
- Abstract
Thrombocytopenia often complicates critical illness and is associated with increased morbidity and mortality. Approaching thrombocytopenia is challenging in the intensive care unit (ICU) because of the multifactorial pathogenesis of this disorder. Interpretation of the platelet count course after ICU admission is helpful to narrow down the cause of thrombocytopenia. Whereas a moderate decrease within the first 3 days is rather typical in severely ill patients, an absent or blunted platelet count increase after 5 days indicates continuing critical illness and a worse outcome. A rapid decrease in platelet counts of more than 50% within 1-2 days, especially if occurring after an intermittent rise, requires immediate attention as it may be a symptom of immune-mediated mechanisms, eg, heparin-induced thrombocytopenia. Treatment should target the underlying disease. Platelet transfusions are indicated in bleeding patients, while there is no strong evidence supporting the usefulness of prophylactic transfusions in ICU patients., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
34. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation.
- Author
-
Thiele T, Kellner S, Hron G, Wasner C, Nauck M, Zimmermann K, Wessel A, Warkentin TE, Greinacher A, and Selleng K
- Subjects
- Blood Coagulation drug effects, Blood Coagulation radiation effects, Blood Component Removal methods, Blood-Borne Pathogens radiation effects, Cold Temperature, Cryopreservation methods, Enzyme Inhibitors pharmacology, Humans, Light, Plasma radiation effects, Blood Banking methods, Blood Preservation methods, Blood-Borne Pathogens drug effects, Methylene Blue pharmacology, Plasma drug effects
- Abstract
Background: Rapid transfusion of fresh-frozen plasma (FFP) is desired for treating coagulopathies, but thawing and issuing of FFP takes more than 40 minutes. Liquid storage of plasma is a potential solution but uncertainties exist regarding clotting factor stability. We assessed different storage conditions of thawed FFP and plasma treated by methylene blue plus light (MB/light) for pathogen inactivation., Study Design and Methods: Fifty thawed apheresis plasma samples (approx. 750 mL) were divided into three subunits and either stored for 7 days at 4°C, at room temperature (RT), and at 4°C after MB/light treatment. Clotting factor activities (Factor [F] II, FV, FVII through FXIII, fibrinogen, antithrombin, von Willebrand factor antigen, Protein C and S) were assessed after thawing and on Days 3, 5, and 7. Changes were classified as "minor" (activities within the reference range) and "major" (activities outside the reference range)., Results: FFP storage at 4°C revealed major changes for FVIII (median [range], 56% [33%-114%]) and Protein S (51% [20%-88%]). Changes were more pronounced when plasma was stored at RT (FVIII, 59% [37%-123%]; FVII, 69% [42%-125%]; Protein S, 20% [10%-35%]). MB/light treatment of thawed FFP resulted in minor changes. However, further storage for 7 days at 4°C revealed major decreases for FVIII (47% [12%-91%]) and Protein S (49% [18%-95%]) and increases for FVII (150% [48%-285%]) and FX (126% [62%-206%])., Conclusion: Storage of liquid plasma at 4°C for 7 days is feasible for FFP as is MB/light treatment of thawed plasma. In contrast, storage of thawed plasma for 7 days at RT or after MB/light treatment at 4°C affects clotting factor stability substantially and is not recommended., (© 2011 American Association of Blood Banks.)
- Published
- 2012
- Full Text
- View/download PDF
35. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.
- Author
-
Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, Ernst F, Selleng K, Weissenborn K, Schmidt BM, Schiffer M, Felix SB, Lerch MM, Kielstein JT, and Mayerle J
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Nervous System Diseases microbiology, Enterohemorrhagic Escherichia coli, Escherichia coli Infections complications, Hemolytic-Uremic Syndrome complications, Immunoglobulin G blood, Immunosorbent Techniques, Nervous System Diseases therapy, Shiga-Toxigenic Escherichia coli
- Abstract
Background: In May 2011, an outbreak of Shiga toxin-producing enterohaemorrhagic E coli O104:H4 in northern Germany led to a high proportion of patients developing post-enteritis haemolytic uraemic syndrome and thrombotic microangiopathy that were unresponsive to therapeutic plasma exchange or complement-blocking antibody (eculizumab). Some patients needed ventilatory support due to severe neurological complications, which arose 1 week after onset of enteritis, suggesting an antibody-mediated mechanism. Therefore, we aimed to assess immunoadsorption as rescue therapy., Methods: In our prospective non-controlled trial, we enrolled patients with severe neurological symptoms and confirmed recent E coli O104:H4 infection without other acute bacterial infection or raised procalcitonin concentrations. We did IgG immunoadsorption processing of 12 L plasma volumes on 2 consecutive days, followed by IgG replacement (0·5 g/kg intravenous IgG). We calculated a composite neurological symptom score (lowest score was best) every day and assessed changes before and after immunoadsorption., Findings: We enrolled 12 patients who initially presented with enteritis and subsequent renal failure; 10 (83%) of 12 patients needed renal replacement therapy by a median of 8·0 days (range 5-12). Neurological complications (delirium, stimulus sensitive myoclonus, aphasia, and epileptic seizures in 50% of patients) occurred at a median of 8·0 days (range 5-15) and mandated mechanical ventilation in nine patients. Composite neurological symptom scores increased in the 3 days before immunoadsorption to 3·0 (SD 1·1, p=0·038), and improved to 1·0 (1·2, p=0·0006) 3 days after immunoadsorption. In non-intubated patients, improvement was apparent during immunoadsorption (eg, disappearance of aphasia). Five patients who were intubated were weaned within 48 h, two within 4 days, and two patients needed continued ventilation for respiratory problems. All 12 patients survived and ten had complete neurological and renal function recovery., Interpretation: Antibodies are probably involved in the pathogenesis of severe neurological symptoms in patients with E coli O104:H4-induced haemolytic uraemic syndrome. Immunoadsorption can safely be used to rapidly ameliorate these severe neurological complications., Funding: Greifswald University and Hannover Medical School., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
36. [Therapy-refractory thrombocytopenia in a 28-year-old patient].
- Author
-
Sauter D, Ostermann H, Selleng K, and Spiekermann K
- Subjects
- Adult, Diagnosis, Differential, Humans, Immune Complex Diseases therapy, Thrombocytopenia therapy, Treatment Outcome, Immune Complex Diseases complications, Immune Complex Diseases diagnosis, Thrombocytopenia diagnosis, Thrombocytopenia etiology
- Abstract
We report a case of a patient with thrombocytopenia. A sporadic MYH9-associated disease, May Hegglin anomaly, was identified by giant platelets, leucocyte inclusion bodies and the typical distribution of NMMHC-IIA in granulocytes in the absence of impaired renal function, cataract and hearing loss. MYH9-associated diseases are an underestimated differential diagnosis of idiopathic thrombocytopenia. The correct diagnosis is important to prevent unnecessary treatment of a patient with thrombocytopenia and to provide sufficient patient information and genetic counseling. Therefore, careful examination of the blood smear has to be the first diagnostic step in a case of unexplained thrombocytopenia.
- Published
- 2011
- Full Text
- View/download PDF
37. Coombs' crossmatch after negative antibody screening--a retrospective observational study comparing the tube test and the microcolumn technology.
- Author
-
Lange J, Selleng K, Heddle NM, Traore A, and Greinacher A
- Subjects
- Blood Grouping and Crossmatching standards, Coombs Test instrumentation, Erythrocytes immunology, Germany, Hospitals, University statistics & numerical data, Humans, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Unnecessary Procedures, Blood Grouping and Crossmatching methods, Coombs Test methods, Isoantibodies blood
- Published
- 2010
- Full Text
- View/download PDF
38. Thrombocytopenia in the intensive care unit patient.
- Author
-
Greinacher A and Selleng K
- Subjects
- Biomarkers metabolism, Hemorrhage complications, Humans, Patient Admission, Platelet Count, Platelet Transfusion, Prognosis, Risk Factors, Thrombocytopenia blood, Thrombocytopenia diagnosis, Thrombocytopenia epidemiology, Intensive Care Units, Thrombocytopenia pathology
- Abstract
The many comorbidities in the severely ill patient also make thrombocytopenia very common (∼40%) in intensive care unit patients. The risk of bleeding is high with severe thrombocytopenia and is enhanced in intensive care patients with mild or moderately low platelet counts when additional factors are present that interfere with normal hemostatic mechanisms (eg, platelet function defects, hyperfibrinolysis, invasive procedures, or catheters). Even if not associated with bleeding, low platelet counts often influence patient management and may prompt physicians to withhold or delay necessary invasive interventions, reduce the intensity of anticoagulation, order prophylactic platelet transfusion, or change anticoagulants due to fear of heparin-induced thrombocytopenia. One approach to identify potential causes of thrombocytopenia that require specific interventions is to consider the dynamics of platelet count changes. The relative decrease in platelet counts within the first 3 to 4 days after major surgery is informative about the magnitude of the trauma or blood loss, whereas the dynamic of the platelet count course thereafter shows whether or not the physiologic compensatory mechanisms are working. A slow and gradual fall in platelet counts developing over 5 to 7 days is more likely to be caused by consumptive coagulopathy or bone marrow failure, whereas any abrupt decrease (within 1-2 days) in platelet counts manifesting after an initial increase in platelet counts approximately 1 to 2 weeks after surgery strongly suggests immunologic causes, including heparin-induced thrombocytopenia, other drug-induced immune thrombocytopenia, and posttransfusion purpura.
- Published
- 2010
- Full Text
- View/download PDF
39. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens.
- Author
-
Selleng K, Schütt A, Selleng S, Warkentin TE, and Greinacher A
- Subjects
- Aged, Aged, 80 and over, Anticoagulants adverse effects, Anticoagulants immunology, Autoantibodies blood, Autoantibodies isolation & purification, B-Lymphocytes cytology, Epitopes, Female, Heparin immunology, Humans, Immunologic Memory immunology, Male, Middle Aged, B-Lymphocytes immunology, Blood Platelets immunology, Enzyme-Linked Immunosorbent Assay methods, Heparin adverse effects, Platelet Factor 4 immunology, Thrombocytopenia chemically induced, Thrombocytopenia diagnosis, Thrombocytopenia immunology
- Abstract
Background: The anti-platelet factor 4 (PF4)/heparin immune response, which underlies heparin-induced thrombocytopenia (HIT), has several atypical features: relatively rapid onset even without previous heparin exposure, lack of immune anamnesis, and transience of antibody production., Study Design and Methods: We modified the enzyme-linked immunosorbent spot (ELISPOT) assay to investigate for PF4/heparin-specific memory B cells in cardiac surgery patients, in whom the high anti-PF4/heparin immunization rate made a prospective study feasible. The PF4-containing antigen complexes were attached to microtiter plates via a spacer, rather than using nitrocellulose, and the final reaction enzyme substrate was added in melted agarose which, after rapid hardening, localized color development of enzyme-tagged anti-immunoglobulin G (IgG) probes to single PF4/heparin-specific B cells. This modified ELISPOT assay was applied to 58 consecutive patients (testing blood from preoperative baseline and Postoperative Days 6 and 10), in which we compared detectability of PF4/heparin-specific B cells to tetanus toxin-specific B cells (comparator group with presumed vaccination)., Results: No patient had detectable PF4/heparin-specific memory B cells at baseline. In 2 of 30 patients (6.7%) who formed anti-PF4/heparin IgG, PF4/heparin-specific memory B cells (three to four spots/well) were detected by Postoperative Day 10, whereas tetanus toxin-specific memory B cells were found in 12 of 24 (50.0%) patients tested (3-25 spots/well; p < 0.001)., Conclusions: HIT lacks a strong memory B-cell response, perhaps explaining transience and lack of anamnesis of the anti-PF4/heparin immune response. The technical modifications we describe for the ELISPOT assay, which permit detection of B-cell reactions to complex antigens, could be useful for studying other immunohematologic disorders, for example, drug-dependent thrombocytopenia and acquired hemophilia.
- Published
- 2010
- Full Text
- View/download PDF
40. Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.
- Author
-
Selleng K, Warkentin TE, Sheppard JA, and Greinacher A
- Subjects
- Antibodies, Anti-Idiotypic isolation & purification, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G immunology, Immunoglobulin G isolation & purification, Antibodies, Anti-Idiotypic immunology, Anticoagulants adverse effects, Heparin adverse effects, Thrombocytopenia chemically induced, Thrombocytopenia immunology
- Abstract
Background: Heparin-induced thrombocytopenia (HIT), which is caused by platelet (PLT)-activating immunoglobulin (Ig)G antibodies against platelet factor 4 (PF4)/heparin complexes, differs from other immune responses seen in immunohematology: IgG antibodies are formed as early as 5 days even without previous heparin exposure; antibodies are remarkably transient (<100 days); HIT is more frequent in postsurgery patients compared with medical patients despite administering the same type and dose of heparin; and increasing evidence implicates autoantibody-like reactivity of anti-PF4/heparin antibodies. We hypothesized that these unusual features could be caused by loss of regulatory anti-idiotype IgM antibodies due to disturbance (e.g., by surgery) of an idiotype-anti-idiotype network., Study Design and Methods: Sera were obtained prospectively before heparin administration and during the immunization phase of HIT and also from patients with previous HIT after waning of antibodies to nondetectable levels. To detect inhibitory IgM anti-idiotype antibodies, we performed serum coincubation experiments and IgG purification by protein G and size filtration to exclude coprecipitating IgM. Sera (n = 3) containing known anti-PF4/heparin IgG or IgM antibodies and normal sera (n = 20) were processed as controls., Results: Fifteen preimmune response sera (seroconverting in the PF4/heparin-IgG enzyme-linked immunosorbent assay only [n = 4] or additionally in a PLT activation assay [n = 5] or in both assays plus thrombosis [n = 6]) and four sera of previously immunized patients were included. Neither did the neat sera inhibit binding of anti-PF4/heparin antibodies nor did the purified IgG fractions show enhanced binding to PF4/heparin complexes., Conclusion: The atypical immunologic features of HIT do not appear to be caused by disruption of an idiotype (IgG)-anti-idiotype (IgM) network.
- Published
- 2009
- Full Text
- View/download PDF
41. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus.
- Author
-
Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, and Seligsohn U
- Subjects
- Adult, False Positive Reactions, Female, Humans, Male, Middle Aged, Thrombocytopenia complications, Thrombocytopenia diagnosis, Antiphospholipid Syndrome complications, Heparin adverse effects, Lupus Erythematosus, Systemic complications, Thrombocytopenia chemically induced
- Abstract
Background: Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy that can be associated with arterial or venous thrombosis and is caused by antibodies against platelet factor 4 (PF4)-heparin complex. Patients with antiphospholipid syndrome (APS) have been reported with positive tests for PF4-heparin complex antibodies by antigen assay. Whether such patients can be treated with heparin is a dilemma., Objectives: To determine the incidence and nature of the HIT immune reaction in patients with APS and/or systemic lupus erythematosus (SLE)., Methods: Antibodies against PF4-heparin complex were assayed by particle gel immunoassay (PaGIA), or enzyme immunoassay (EIA) with or without an excess of heparin. EIA for PF4 alone was also performed. Functional assays for HIT, that is, heparin-induced platelet activation (HIPA) and heparin-induced platelet aggregation, were also performed., Results: In 32 of 42 patients (76.2%) with APS, APS and SLE, SLE, or SLE with antiphospholipid antibodies, EIA IgG or PaGIA for PF4-heparin complex antibodies were positive. Of these 32 samples, 26 (81.3%) tested positive for anti-PF4 antibodies. All 24 samples that were positive for PF4-heparin complex by EIA IgG were also positive for EIA IgG in the presence of heparin excess, and all were negative by the HIPA and heparin-induced platelet aggregation tests., Conclusion: A large proportion of patients with APS and/or SLE give false-positive HIT antigen test results that are presumably related to autoantibodies against PF4, which can be distinguished from true HIT antibodies by EIA for PF4-heparin complexes tested with heparin excess, and by functional assays.
- Published
- 2009
- Full Text
- View/download PDF
42. Management of emergency cardiac surgery in a patient with alloanti-Ge2.
- Author
-
Selleng S, Selleng K, Zawadzinski C, Wollert HG, Yürek S, and Greinacher A
- Subjects
- Aged, Blood Group Incompatibility immunology, Blood Grouping and Crossmatching, Humans, Male, ABO Blood-Group System immunology, Blood Transfusion methods, Cardiac Surgical Procedures, Emergency Medical Services methods, Isoantibodies blood
- Abstract
Transfusion management of patients alloimmunized against high-prevalence erythrocyte antigens is often problematic in emergency situations. In these patients, incompatible transfusion may be less harmful for the patient than delaying surgery, especially if the antibody is not clinically significant. We report an untransfused 75-year-old Caucasian man (blood group O) with an alloantibody against the Gerbich-2 (Ge2) antigen who required emergency cardiac surgery. Because cross-match compatible blood was not available in an acceptable timeframe, we performed a 'biological cross-match' with sequential transfusion of 20 and 50 mL and then the entire unit of incompatible red blood cells (RBCs) before surgery. When there were no clinical symptoms of adverse biological effects, we transfused two further incompatible packed RBCs during surgery. Subsequently, there was neither clinical nor laboratory evidence of major intra- or extravascular haemolysis, suggesting that this anti-Ge2 antibody was not clinically significant.
- Published
- 2009
- Full Text
- View/download PDF
43. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.
- Author
-
Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, and Greinacher A
- Subjects
- Adult, Arginine analogs & derivatives, Autoantibodies blood, Autoantibodies immunology, Heart Failure blood, Heart Failure immunology, Heparin immunology, Hirudins administration & dosage, Humans, Male, Middle Aged, Pipecolic Acids administration & dosage, Platelet Factor 4 immunology, Recombinant Proteins administration & dosage, Sulfonamides, Thrombocytopenia immunology, Anticoagulants administration & dosage, Anticoagulants adverse effects, Heart Failure surgery, Heart Transplantation immunology, Heparin administration & dosage, Heparin adverse effects, Thrombocytopenia blood, Thrombocytopenia chemically induced
- Abstract
Anticoagulation management of patients with recent heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB) surgery is a serious challenge, and especially difficult in patients requiring urgent heart transplantation. As nonheparin anticoagulants during CPB bear a high risk of major bleeding, these patients are at risk of being taken off the transplant list. Short-term use of unfractionated heparin (UFH) for CPB, with restriction of UFH to the surgery itself, is safe and effective in patients with a history of HIT who test negative for antiplatelet factor 4 (PF4)/heparin antibodies. We present evidence that it is safe to expand the concept of UFH reexposure to patients with subacute HIT (ie, those patients with recent HIT in whom the platelet count has recovered but in whom anti-PF4/heparin IgG antibodies remain detectable) requiring heart transplantation, if they test negative by a sensitive functional assay using washed platelets. This can be lifesaving in patients with end-stage heart failure.
- Published
- 2008
- Full Text
- View/download PDF
44. Errors in patient specimen collection: application of statistical process control.
- Author
-
Dzik WS, Beckman N, Selleng K, Heddle N, Szczepiorkowski Z, Wendel S, and Murphy M
- Subjects
- Blood Banks statistics & numerical data, Blood Group Incompatibility epidemiology, Data Interpretation, Statistical, Humans, International Cooperation, Medical Errors statistics & numerical data, Medical Records statistics & numerical data, Risk Reduction Behavior, Software, Blood Banks standards, Blood Group Incompatibility prevention & control, Blood Specimen Collection standards, Blood Specimen Collection statistics & numerical data, Blood Transfusion standards, Medical Errors prevention & control
- Abstract
Background: Errors in the collection and labeling of blood samples for pretransfusion testing increase the risk of transfusion-associated patient morbidity and mortality. Statistical process control (SPC) is a recognized method to monitor the performance of a critical process. An easy-to-use SPC method was tested to determine its feasibility as a tool for monitoring quality in transfusion medicine., Study Design and Methods: SPC control charts were adapted to a spreadsheet presentation. Data tabulating the frequency of mislabeled and miscollected blood samples from 10 hospitals in five countries from 2004 to 2006 were used to demonstrate the method. Control charts were produced to monitor process stability., Results: The participating hospitals found the SPC spreadsheet very suitable to monitor the performance of the sample labeling and collection and applied SPC charts to suit their specific needs. One hospital monitored subcategories of sample error in detail. A large hospital monitored the number of wrong-blood-in-tube (WBIT) events. Four smaller-sized facilities, each following the same policy for sample collection, combined their data on WBIT samples into a single control chart. One hospital used the control chart to monitor the effect of an educational intervention., Conclusion: A simple SPC method is described that can monitor the process of sample collection and labeling in any hospital. SPC could be applied to other critical steps in the transfusion processes as a tool for biovigilance and could be used to develop regional or national performance standards for pretransfusion sample collection. A link is provided to download the spreadsheet for free.
- Published
- 2008
- Full Text
- View/download PDF
45. Heparin-induced thrombocytopenia in intensive care patients.
- Author
-
Selleng K, Selleng S, and Greinacher A
- Subjects
- Anticoagulants administration & dosage, Critical Illness, Hemorrhage etiology, Hemorrhage pathology, Heparin therapeutic use, Humans, Platelet Aggregation Inhibitors administration & dosage, Platelet Count, Risk Factors, Thrombocytopenia epidemiology, Thrombosis drug therapy, Thrombosis pathology, Anticoagulants therapeutic use, Critical Care, Heparin adverse effects, Platelet Aggregation Inhibitors therapeutic use, Thrombocytopenia diagnosis, Thrombocytopenia etiology
- Abstract
Heparin-induced thrombocytopenia (HIT) is a serious, prothrombotic, immune-mediated complication of heparin therapy that can cause limb- and life-threatening thromboembolic events. Prompt diagnosis and therapeutic dose anticoagulation by an alternative anticoagulant are crucial to improve clinical outcome. In critically ill patients, the diagnosis of HIT is difficult due to the high incidence of thrombocytopenia, often caused by reasons other than HIT, and the high incidence of clinically irrelevant, non-platelet-activating anti-PF4-heparin antibodies. Also, treatment of HIT is problematic in these patients. No antidote is available for any of the alternative anticoagulants, and their half-lives are often prolonged in the presence of renal or hepatic insufficiency. This increases the risk of bleeding complications and mandates careful balancing of both risks, thrombosis and bleeding. Therefore, accurate diagnosis of HIT and individual choice of alternative anticoagulant are important for the adequate management of critically ill HIT patients.
- Published
- 2008
- Full Text
- View/download PDF
46. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass.
- Author
-
Selleng S, Selleng K, Wollert HG, Muellejans B, Lietz T, Warkentin TE, and Greinacher A
- Subjects
- Aged, Anticoagulants pharmacology, Blood Platelets metabolism, Cardiopulmonary Bypass, Female, Heparin adverse effects, Humans, Intensive Care Units, Male, Middle Aged, Platelet Count, Prospective Studies, Retrospective Studies, Thrombocytopenia chemically induced, Thrombocytopenia diagnosis, Heparin chemistry, Thrombocytopenia blood
- Abstract
Background: The diagnosis of heparin-induced thrombocytopenia (HIT) is problematic in postcardiac surgery (CS) intensive care unit (ICU) patients, as there are multiple potential explanations for thrombocytopenia and the presence of anti-platelet factor 4/heparin antibodies is not highly specific for HIT. Two platelet count profiles for HIT - a 40% or greater fall in platelet count beginning on or after day 5 (pattern 1) and persisting thrombocytopenia (< 100 x 10(9) L(-1)) beyond day 7 (pattern 2) - have been described in post-CS patients., Methods and Results: We examined the platelet count profiles of 329 consecutive post-CS patients who required ICU treatment beyond 7 days. Although 70 patients (21.3%) developed thrombocytopenia (57.1% pattern 1, 42.9% pattern 2), the overall incidence of HIT was only 1.8% [6/329; 95% confidence interval (95% CI) 0.7-3.9%] in these ICU patients, with more HIT patients showing a pattern 2 than a pattern 1 platelet count decrease (four vs. two patients). Notably, pattern 2 patients with HIT also showed a new proportional fall of > 30% in platelet count between postoperative days 5 and 10. Among the remaining 2242 post-CS patients without a prolonged ICU stay, only three (0.1%; 95% CI 0.03-0.4%) developed symptomatic HIT (OR 0.07; 95% CI 0.01-0.3; P = 0.0002 vs. ICU patients), all presenting with pattern 1., Conclusions: Among post-CS ICU patients, a postoperative platelet count fall between days 5 and 10 increases diagnostic specificity for HIT, irrespective of whether this platelet count fall occurs after postoperative platelet count recovery (pattern 1) or is superimposed upon persisting postoperative thrombocytopenia (pattern 2). A prospective study is required in order to validate the findings of this retrospective analysis.
- Published
- 2008
- Full Text
- View/download PDF
47. Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).
- Author
-
Selleng K, Lubenow LE, Greinacher A, and Warkentin TE
- Subjects
- Adult, Humans, Male, Mutation, Premedication, Pulmonary Embolism drug therapy, Pulmonary Embolism etiology, Syndrome, Thrombocytopenia drug therapy, Molecular Motor Proteins genetics, Myosin Heavy Chains genetics, Perioperative Care, Thrombocytopenia etiology
- Abstract
Objective: Hereditary thrombocytopenias characterized by mutations in the gene for non-muscle myosin heavy chain IIA (NMMHC-IIA) are known as MYH9-related hereditary macrothrombocytopenia, and include the May-Hegglin anomaly, Sebastian platelet syndrome, Fechtner syndrome, and Epstein syndrome. Despite the presence of thrombocytopenia, these patients often have only mild or non-bleeding phenotypes. A major risk for these patients can be inappropriate treatment with long-term corticosteroids or splenectomy for misdiagnosed chronic autoimmune thrombocytopenia, as well as inadequate peri- and postoperative management., Methods: Using the case of a 44-yr-old male with Fechtner syndrome (macrothrombocytopenia, leukocyte inclusions, sensorineural deafness, glomerulonephritis) who underwent neurosurgery for an intracerebral arteriovenous malformation, we describe current methods to diagnose hereditary MYH9-related macrothombocytopenia by analysis of the blood smear, immunofluorescence staining of the NMMHC-IIA in leucocytes, and by MYH9-gene sequencing., Results: Clusters of NMMHC-IIA in granulocytes and a R1165C mutation in the MYH9-gene in two macrothrombocytopenic family members confirmed the diagnosis of a MYH9-related disease. The patient had no bleeding diathesis by history or physical examination. Thus no perioperative prohemostatic pharmacologic therapies or transfusions were given, with only minimal bleeding observed. Postoperative antithrombotic thromboprophylaxis was not given because of anticipated enhanced risk for bleeding. However, the patient developed symptomatic pulmonary embolism on postoperative day 6, which was successfully managed with 8 months of anticoagulation., Conclusion: MYH9-related hereditary macrothrombocytopenia does not necessarily protect against postoperative venous thromboembolism, and affected patients who do not evince bleeding diathesis should be considered for routine postoperative pharmacologic thromboprophylaxis.
- Published
- 2007
- Full Text
- View/download PDF
48. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.
- Author
-
Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, and Warkentin TE
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Platelet Activation, Platelet Aggregation Inhibitors chemistry, Prospective Studies, Heparin immunology, Heparin pharmacology, Immunoglobulin A chemistry, Immunoglobulin G chemistry, Immunoglobulin M chemistry, Platelet Factor 4 immunology, Thrombocytopenia chemically induced
- Abstract
Introduction: Platelet-activating antiplatelet factor 4/heparin (anti-PF4/heparin) antibodies are the major cause of heparin-induced thrombocytopenia (HIT). However, the relative utility of functional (platelet activation) vs. antigen [enzyme-immunoassay (EIA)] assays, and the significance of assay discrepancies remain unresolved., Methods: Consecutive patient sera (n = 1650) referred for diagnostic HIT testing were screened prospectively by both the heparin-induced platelet activation (HIPA) test and anti-PF4/heparin EIA - including individual classes (IgG, IgA, IgM) - with clinical correlations studied. Platelet microparticle and annexin-V-binding properties of the sera were also investigated., Results: Only 205 (12.4%) sera tested positive in either the HIPA and/or EIA: 95 (46.3%) were positive in both, 109 (53.1%) were only EIA-positive, and, notably, only one serum was HIPA-positive/EIA-negative. Of 185 EIA-positive sera, only 17.6% had detectable IgM and/or IgA without detectable IgG. Among sera positive for EIA IgG, optical density values were higher when the sera were HIPA-positive (1.117 vs. 0.768; P < 0.0001), with widely overlapping values. Two HIPA-positive but EIA-IgG-negative sera became HIPA-negative following IgG depletion, suggesting platelet-activating antibodies against non-PF4-dependent antigens. Clinical correlations showed that HIPA-negative/EIA-positive patients did not develop thrombosis and had reasons other than HIT to explain thrombocytopenia. IgM/A antibodies did not increase microparticle penetration, but increased annexin-V binding., Conclusions: The anti-PF4/heparin EIA has high ( approximately 99%) sensitivity for HIT. However, only about half of EIA-positive patients are likely to have HIT. Anti-PF4/heparin antibodies of IgM/A class and non-PF4-dependent antigens have only a minor role in HIT.
- Published
- 2007
- Full Text
- View/download PDF
49. Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: role of monocyte procoagulant activity induced by bacterial supernatant.
- Author
-
Selleng K, Warkentin TE, Greinacher A, Morris AM, Walker IR, Heggtveit HA, Eichler P, and Cybulsky IJ
- Subjects
- Cells, Cultured, Factor Xa biosynthesis, Humans, Male, Middle Aged, Platelet Count, Purpura, Thrombotic Thrombocytopenic drug therapy, Purpura, Thrombotic Thrombocytopenic etiology, Purpura, Thrombotic Thrombocytopenic metabolism, Staphylococcal Infections complications, Staphylococcal Infections drug therapy, Staphylococcal Infections metabolism, Staphylococcus epidermidis drug effects, Thrombocytopenia drug therapy, Thrombocytopenia etiology, Thrombocytopenia metabolism, Blood Coagulation, Hemolysis drug effects, Lymphocytes cytology, Purpura, Thrombotic Thrombocytopenic pathology, Staphylococcal Infections pathology, Staphylococcus epidermidis physiology, Thrombocytopenia pathology
- Abstract
The pathogenesis of very severe thrombocytopenia in bacterial endocarditis is uncertain. We report a 50-year-old male with platelet counts < 10 x 10(9)/l and fragmentation hemolysis complicating Staphylococcus epidermidis pacemaker endocarditis with a giant vegetation. Antibiotics, corticosteroids, high-dose intravenous gammaglobulin, and plasmapheresis (for initially-suspected thrombotic thrombocytopenic purpura) failed to produce significant platelet count increase. However, therapeutic-dose heparin anticoagulation was associated with a platelet count increase from <10 to approximately 40 x 10(9)/l, with parallel reduction in thrombin-antithrombin complexes (from 8.9 to 3.5 microg/l), facilitating surgical intervention. The thrombocytopenia promptly resolved following surgical removal of the vegetation. Culture supernatant from S. epidermidis isolated from the patient's blood induced monocytes to express procoagulant activity (assessed by factor Xa generation) equivalent to lipopolysaccharide (1 microg/ml), with half-maximal activation seen with culture supernatant diluted to 1:12,800. These data are consistent with previous animal models of endocarditis demonstrating staphylococci-induced procoagulant changes in monocytes. This case demonstrates that heparin anticoagulation can be therapeutic in infective endocarditis-associated severe thrombocytopenia in a non-bleeding patient, and that such therapy may ameliorate the platelet count enough to permit surgical intervention.
- Published
- 2007
- Full Text
- View/download PDF
50. Mistransfusion in the emergency room.
- Author
-
Selleng S, Selleng K, Friesecke S, Haupt B, and Greinacher A
- Subjects
- Blood Grouping and Crossmatching, Blood Transfusion methods, Emergency Service, Hospital, Germany, Humans, Male, Middle Aged, Shock, Hemorrhagic therapy, Emergency Medical Services, Medical Errors prevention & control, Transfusion Reaction
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.